Design (Testphase)
Risk & Weakness
Pradeep Bonde: 4% Breakout Bearish
26
Findings
August 3, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Bonde's downside counterpart (original Stockbee formula 'c/c1 ≤ 0.96'): a daily loss of at least 4% on above-average volume (relative volume above 1) — a downside momentum burst that often triggers further weak days. Minimum daily volume 100,000 shares, price above $3 (penny-stock filter).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(17)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Breakout
- The price clears a level where it previously failed multiple times (top of a base, an old high) - ideally on clearly elevated volume. For many momentum strategies, the breakout is the actual buy signal.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Momentum
- The driving force behind a price trend: stocks that have recently risen sharply statistically tend to keep rising more often than not. Momentum strategies therefore buy strength - not perceived bargains.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience, Inc. | 08/12 | — | 89 8/22 | Stage 2 | D 26 | 2 of 9 | 1.0 $ | Biotechnology | – | — | — | Healthcare | 27.10 $ | +37.3 % | +41.2 % | +781.8 % | −11.0 % | +31.5 % | 99 | 42 | 8.0 % | 7.7 % | 1.07 | — | 0.0 | — | 3.9 | — | — | 0.0 | — | — | 0.0 % | -38.9 % | -21.7 % | 0.02 | — | -100.0 % | — | 0.0 % | 0.0 % | 12.7 | 82.1 % | 9.4 % | 4.6 (8) |
| GLUE Monte Rosa Therapeutics Inc | 08/06 | +19 % | — | Stage 2 | D 35 | 4 of 9 | 0.0 $ | Biotechnology | Uses AI | — | Healthcare | 16.50 $ | +32.1 % | +35.5 % | +233.7 % | −16.0 % | +53.1 % | 96 | 50 | 8.1 % | 6.8 % | 1.56 | — | 10.9 | — | 2.5 | — | — | 51.9 | — | -238.5 % | 0.0 % | -32.6 % | -16.4 % | 0.08 | — | +63.5 % | — | 0.0 % | 0.0 % | 7.7 | 113.2 % | 20.7 % | — | |
| COGT Cogent Biosciences Inc | 08/04 | +12 % | 26 3/22 | Stage 1 | D 41 | 4 of 9 | 6.6 $ | Biotechnology | – | — | — | Healthcare | 38.90 $ | +2.2 % | -2.5 % | +240.9 % | −13.1 % | +39.5 % | 95 | 42 | 4.5 % | 4.5 % | 0.34 | — | 0.0 | — | 12.1 | — | — | -3.9 | 0.0 % | — | 0.0 % | -85.7 % | -38.1 % | 0.39 | 67.3 % | -100.0 % | — | 0.0 % | 0.0 % | 4.1 | 112.3 % | 9.8 % | 4.2 (12) |
| NVCT Nuvectis Pharma Inc | 08/04 | +1 % | 82 7/22 | Stage 2 | E 24 | 1 of 9 | 0.7 $ | Biotechnology | – | — | — | Healthcare | 21.50 $ | +132.5 % | +270.0 % | +209.2 % | −0.2 % | +47.9 % | 95 | 42 | 16.4 % | 9.8 % | -0.25 | — | 0.0 | — | — | — | — | -7.4 | — | — | 0.0 % | -154.4 % | -63.6 % | — | — | -100.0 % | — | 0.0 % | 0.0 % | -7.1 | 18.2 % | 7.3 % | 4.3 (6) |
| STRZ Starz Entertainment LLC | — | — | — | Stage 2 | E 19 | 4 of 9 | 0.0 $ | Entertainment | – | — | — | Communication Services | 26.00 $ | +143.2 % | +152.5 % | +78.8 % | −9.7 % | +15.0 % | 94 | 50 | 6.8 % | 7.1 % | — | — | 3.6 | — | — | — | — | 1.7 | — | 50.7 % | -13.2 % | -34.7 % | -0.8 % | — | — | -8.2 % | — | 0.0 % | 0.0 % | 1.3 | 92.3 % | 3.7 % | — |
| AVR Anteris Technologies Global Corp. Common Stock | 08/10 | — | 70 6/22 | Stage 2 | D 31 | 4 of 9 | 0.8 $ | Medical Instruments & Supplies | – | — | — | Healthcare | 7.80 $ | +106.0 % | +80.8 % | +144.2 % | −6.4 % | +96.6 % | 94 | 42 | 6.4 % | 6.9 % | 0.73 | — | 0.0 | 421.7 | — | — | — | 0.0 | — | 74.3 % | 0.0 % | -59.2 % | -34.0 % | — | — | -29.2 % | — | 0.0 % | 0.0 % | 20.7 | 66.1 % | 11.9 % | 4.8 (4) |
| CGEM Cullinan Oncology LLC | 08/06 | +14 % | 55 5/22 | Stage 2 | C 47 | 1 of 9 | 1.0 $ | Biotechnology | – | — | — | Healthcare | 16.50 $ | +71.5 % | +79.5 % | +112.4 % | −1.5 % | +91.7 % | 93 | 42 | 8.3 % | 8.2 % | -0.01 | — | 6.7 | — | — | — | — | -1.5 | — | — | 0.0 % | -48.2 % | -30.6 % | — | — | -100.0 % | — | 0.0 % | 0.0 % | 10.2 | 107.8 % | 23.8 % | 4.9 (9) |
| CCCC C4 Therapeutics Inc | 08/06 | -23 % | 57 5/22 | Stage 2 | D 37 | 4 of 9 | 0.4 $ | Biotechnology | – | — | — | Healthcare | 3.50 $ | +120.9 % | +109.1 % | +69.8 % | −4.3 % | +281.0 % | 93 | 42 | 7.7 % | 9.3 % | 2.91 | — | 0.0 | 11.4 | 1.7 | — | — | -0.4 | — | 78.3 % | -297.8 % | -48.4 % | -19.9 % | 0.25 | — | +1.0 % | — | 0.0 % | 0.0 % | 0.5 | 85.1 % | 21.7 % | 4.0 (8) |
| ARMP Armata Pharmaceuticals Inc | 08/11 | +51 % | 56 5/22 | Stage 1 | D 29 | 4 of 9 | 0.2 $ | Biotechnology | Neutral | — | — | Healthcare | 4.50 $ | +11.6 % | +0.8 % | +85.3 % | −60.2 % | +169.2 % | 91 | 42 | 11.0 % | 10.5 % | 1.27 | — | 0.0 | 31.3 | — | — | — | -3.5 | — | -215.2 % | 0.0 % | -3,439.4 % | -25.3 % | — | — | -5.2 % | — | 0.0 % | 0.0 % | -52.2 | 10.5 % | 1.9 % | — |
| AVTX Avalo Therapeutics Inc | 08/06 | -33 % | 41 4/22 | Stage 3 | E 17 | 2 of 9 | 1.0 $ | Biotechnology | – | — | — | Healthcare | 18.30 $ | -1.8 % | +2.0 % | +131.3 % | −25.8 % | +144.2 % | 91 | 42 | 7.7 % | 7.4 % | 0.79 | — | 0.0 | 9,860.0 | — | — | — | -0.2 | — | -66,988.1 % | 0.0 % | -88.8 % | -41.5 % | — | — | -86.6 % | — | 0.0 % | 0.0 % | -10.4 | 76.6 % | 24.0 % | 4.6 (8) |
| MNPR Monopar Therapeutics Inc | 08/11 | -10 % | 89 8/22 | Stage 3 | D 32 | 4 of 9 | 0.6 $ | Biotechnology | Neutral | — | Healthcare | 108.40 $ | +25.2 % | +33.6 % | +163.1 % | −16.5 % | +7.8 % | 87 | 42 | 8.6 % | 7.6 % | 1.48 | — | 0.0 | — | 5.4 | — | — | -2.4 | — | — | 0.0 % | -15.9 % | -12.1 % | 0.00 | — | -100.0 % | — | 0.0 % | 0.0 % | 62.2 | 93.3 % | 29.7 % | 4.2 (5) | |
| MIRM Mirum Pharmaceuticals Inc | 08/05 | +102 % | 68 6/22 | Stage 2 | C 45 | 3 of 9 | 6.3 $ | Biotechnology | – | — | — | Healthcare | 106.00 $ | +40.6 % | +52.3 % | +105.0 % | −1.9 % | +38.2 % | 86 | 42 | 5.0 % | 5.0 % | 0.49 | — | 39.7 | 11.0 | 28.1 | — | — | 341.2 | -39.5 % | 81.4 % | -140.2 % | -335.8 % | -5.9 % | 1.34 | 27.2 % | +54.7 % | — | 0.0 % | 0.0 % | -5.4 | 114.4 % | 15.6 % | 4.6 (10) |
| SLDB Solid Biosciences LLC | 08/11 | +20 % | 55 5/22 | Stage 2 | D 26 | 3 of 9 | 0.8 $ | Biotechnology | – | — | — | Healthcare | 8.10 $ | +55.9 % | +60.5 % | +17.8 % | −9.4 % | +118.9 % | 86 | 42 | 8.4 % | 7.5 % | 2.36 | — | 0.0 | — | 2.1 | — | — | -3.7 | — | — | 0.0 % | -57.4 % | -32.0 % | 0.06 | — | -100.0 % | — | 0.0 % | 0.0 % | 6.1 | 101.6 % | 20.7 % | 4.6 (12) |
| MARA Marathon Digital Holdings Inc | 08/04 | +5 % | 54 5/22 | Stage 3 | D 26 | 4 of 9 | 4.4 $ | Capital Markets | – | — | — | Financial Services | 11.30 $ | +63.7 % | +41.1 % | -29.6 % | −40.8 % | +60.4 % | 76 | 84 | 10.0 % | 8.7 % | 5.37 | — | 39.5 | 5.0 | 2.0 | — | 0.10 | 3.3 | -558.1 % | 45.3 % | -234.8 % | -67.3 % | -15.6 % | 1.15 | 45.1 % | +38.2 % | — | 0.0 % | 0.0 % | 1.6 | 69.6 % | 33.2 % | 3.5 (15) |
| PTCT PTC Therapeutics Inc | 08/06 | +33 % | 68 6/22 | Stage 2 | C 53 | 2 of 9 | 5.6 $ | Biotechnology | – | — | — | Healthcare | 68.00 $ | +8.1 % | +4.1 % | +30.5 % | −3.4 % | +42.5 % | 75 | 42 | 4.7 % | 4.0 % | 0.53 | — | 35.6 | 5.6 | 1,402.7 | — | 0.81 | 23.9 | 16.5 % | 50.0 % | -3.8 % | -7,740.1 % | 2.5 % | -2.19 | -6.3 % | +114.5 % | — | 0.0 % | 0.0 % | 2.5 | 117.7 % | 16.1 % | 3.9 (14) |
| NPCE Neuropace Inc | 08/11 | +85 % | — | Stage 2 | C 49 | 2 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 12.90 $ | +3.1 % | +2.1 % | +51.5 % | −16.5 % | +22.2 % | 74 | 50 | 4.7 % | 4.7 % | 1.89 | — | 0.0 | — | 32.2 | — | — | -16.9 | — | 78.3 % | -21.7 % | -111.4 % | -10.0 % | 4.88 | — | +25.1 % | — | 0.0 % | 0.0 % | -11.4 | 96.3 % | 2.1 % | — |
| XNCR Xencor Inc | 08/05 | -15 % | 14 2/22 | Stage 3 | D 32 | 2 of 9 | 1.5 $ | Biotechnology | – | — | — | Healthcare | 20.20 $ | -8.0 % | +1.0 % | +142.9 % | −21.1 % | +40.3 % | 69 | 42 | 6.5 % | 5.7 % | 0.86 | — | 68.0 | 15.3 | 3.0 | — | — | -17.3 | — | -152.2 % | -177.1 % | -29.8 % | -16.2 % | 0.34 | — | +13.7 % | — | 0.0 % | 0.0 % | 4.0 | 115.5 % | 20.8 % | 4.5 (12) |
| VKTX Viking Therapeutics Inc | 07/22 | -8 % | 54 5/22 | Stage 3 | E 19 | 1 of 9 | 3.7 $ | Biotechnology | – | — | — | Healthcare | 31.70 $ | -1.1 % | +5.9 % | -2.6 % | −14.3 % | +193.4 % | 59 | 42 | 6.8 % | 5.3 % | 0.66 | — | 0.0 | — | — | — | — | -71.6 | 0.0 % | — | 0.0 % | -70.0 % | -42.5 % | — | 82.5 % | -100.0 % | — | 0.0 % | 0.0 % | 3.0 | 64.5 % | 21.1 % | 4.4 (19) |
| EYPT Eyepoint Pharmaceuticals Inc | 08/05 | -8 % | 69 6/22 | Stage 1 | D 34 | 1 of 9 | 1.0 $ | Biotechnology | – | — | — | Healthcare | 12.30 $ | -21.3 % | -22.7 % | +24.8 % | −28.3 % | +229.3 % | 59 | 42 | 6.7 % | 6.3 % | 1.74 | — | 6.2 | 136.3 | 4.5 | — | — | 11.6 | — | -2,951.8 % | 0.0 % | -102.7 % | -54.1 % | 0.09 | — | -27.5 % | — | 0.0 % | 0.0 % | -7.3 | 111.8 % | 20.7 % | 4.7 (13) |
| HOV Hovnanian Enterprises Inc | 08/20 | +13 % | 8 2/31 | Stage 3 | D 37 | 2 of 9 | 0.7 $ | Residential Construction | – | — | — | Consumer Cyclical | 123.90 $ | +30.7 % | +43.6 % | +3.7 % | −12.5 % | -40.3 % | 56 | 21 | 6.9 % | 6.5 % | 1.81 | 35.7 | 13.5 | 0.2 | 1.1 | 2.6 | 2.00 | 14.0 | — | 15.2 % | 1.3 % | 4.4 % | 2.0 % | 1.13 | — | -0.9 % | — | 0.0 % | 0.0 % | 7.4 | 65.0 % | 7.3 % | 3.0 (1) |
| RGNX Regenxbio Inc | 08/06 | -16 % | 15 2/22 | Stage 4 | D 27 | 1 of 9 | 0.5 $ | Biotechnology | – | — | — | Healthcare | 9.70 $ | -30.9 % | -18.2 % | +13.9 % | −36.8 % | +150.2 % | 46 | 42 | 13.1 % | 9.4 % | 0.90 | — | 0.0 | 5.6 | — | — | 0.26 | -3.4 | — | -196.6 % | 0.0 % | -196.4 % | -38.5 % | — | — | +104.5 % | — | 0.0 % | 0.0 % | -10.9 | 84.7 % | 18.0 % | 4.4 (12) |
| OLN Olin Corporation | 07/30 | -17 % | 75 7/23 | Stage 1 | D 43 | 3 of 9 | 2.1 $ | Chemicals | – | — | — | Basic Materials | 18.50 $ | +4.6 % | +2.5 % | +1.0 % | −29.8 % | +41.3 % | 30 | 2 | 6.7 % | 4.7 % | 1.21 | — | 42.7 | 0.3 | 1.2 | 16.4 | 7.05 | 13.0 | -4.2 % | 6.9 % | -2.9 % | -9.8 % | 0.3 % | 1.91 | 23.6 % | +3.7 % | — | 4.3 % | 173.9 % | 5.0 | 106.2 % | 14.5 % | 3.3 (16) |
| METC Ramaco Resources Inc | 07/30 | +22 % | 86 8/23 | Stage 4 | D 26 | 3 of 9 | 0.6 $ | Coking Coal | Neutral | — | Basic Materials | 9.20 $ | -45.7 % | -56.7 % | -54.9 % | −82.1 % | +167.7 % | 21 | 4 | 6.7 % | 7.4 % | 1.26 | — | 5.5 | 1.1 | 1.4 | — | — | 1,123.0 | -20.0 % | 14.5 % | -11.5 % | -15.2 % | -4.8 % | 0.95 | 42.4 % | -19.5 % | — | 0.0 % | 500.0 % | 1.4 | 91.5 % | 56.0 % | 5.0 (3) | |
| PSFE Paysafe Ltd | 08/11 | -13 % | 47 5/25 | Stage 4 | D 40 | 4 of 9 | 0.4 $ | Software - Infrastructure | Uses AI | — | Technology | 8.10 $ | -19.0 % | -10.4 % | -33.5 % | −55.9 % | +21.9 % | 12 | 42 | 5.5 % | 5.8 % | 1.75 | — | 3.6 | 0.2 | 0.7 | 2.5 | — | 8.0 | — | 56.4 % | -11.4 % | -27.0 % | 1.6 % | 4.11 | — | -0.2 % | — | 0.0 % | 0.0 % | 2.1 | 59.4 % | 13.2 % | 3.0 (7) | |
| MSTR MicroStrategy Incorporated | 07/30 | +72 % | 10 2/25 | Stage 4 | D 25 | 4 of 9 | 35.2 $ | Software - Application | – | — | — | Technology | 93.30 $ | -31.7 % | -41.6 % | -76.8 % | −81.3 % | +183.3 % | 4 | 7 | 9.2 % | 7.7 % | 3.55 | — | 1.7 | 71.7 | 0.9 | — | 2.85 | 179.2 | -11,641.5 % | 67.6 % | 0.0 % | -30.8 % | -38.7 % | 0.18 | 84.1 % | +3.0 % | — | 0.0 % | 0.0 % | 6.9 | 64.0 % | 11.8 % | 4.3 (13) |
| BRBR Bellring Brands LLC | 08/03 | -23 % | 65 4/16 | Stage 4 | D 37 | 2 of 9 | 1.3 $ | Packaged Foods | – | — | — | Consumer Defensive | 12.40 $ | -57.8 % | -58.9 % | -77.3 % | −81.1 % | +14.6 % | 3 | 18 | 8.3 % | 7.1 % | 0.52 | — | 8.8 | 0.6 | — | 7.0 | — | 8.3 | 11.2 % | 30.2 % | 6.8 % | 61.5 % | 18.5 % | — | -48.6 % | +16.1 % | — | 0.0 % | 0.0 % | 8.8 | 109.9 % | 14.5 % | 4.4 (17) |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Bonde's downside counterpart (original Stockbee formula 'c/c1 ≤ 0.96'): a daily loss of at least 4% on above-average volume (relative volume above 1) — a downside momentum burst that often triggers further weak days. Minimum daily volume 100,000 shares, price above $3 (penny-stock filter).
All scanners are recalculated daily across the entire stock universe — most recently on 3. August 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 26 stocks pass this scanner's criteria (as of 3. August 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.